Nutex Health Inc (NUTX)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $1.19B
Last updated: Nov 17, 2026 at 4:15 PM ET
Nutex Health Inc (NUTX) Stock Chart
Nutex Health (NUTX) has a latest price of $174.51 on Nov 17, 2026, 22.8% below its 52-week high of $226.16. Its price rose 62.9% over the past 12 months. The month-end price fell 95.9% over the 10 years through Oct 2026, a compound annual decline of 27.3%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $24,737.63 in Sep 2017 and its lowest $5.95 in Jun 2024, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart NUTX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for NUTX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 8.5%, and over 6 months it rose 38.1%. The month-end price rose 544.9% over the 3 years through Oct 2026, a compound annual rate of 86.1%.
| Period | Change |
|---|---|
| 1 month | -8.8% |
| 3 months | -8.5% |
| 6 months | +38.1% |
| 12 months | +62.9% |
| 12 months, with dividends | +62.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +544.9% | +86.1% |
| 5 years | -66.6% | -19.7% |
| 10 years | -95.9% | -27.3% |
Price by Year
Its best calendar year was 2025, when the price rose 419.5%, and its weakest was 2023, when it fell 90.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $200.15 | +21.6% |
| 2025 | $164.62 | +419.5% |
| 2024 | $31.69 | +17.4% |
| 2023 | $26.99 | -90.5% |
| 2022 | $284.86 | -53.9% |
| 2021 | $617.69 | +205.2% |
| 2020 | $202.40 | -32.5% |
| 2019 | $299.85 | -20.0% |
| 2018 | $374.81 | -90.0% |
| 2017 | $3,748.13 | -28.6% |
Trading Range
The price is 13.4% below its 50-day average of $201.51 and 14.7% above its 200-day average of $152.18.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $174.51 | |
| 52-week high | $226.16 | -22.8% |
| 52-week low | $83.99 | +107.8% |
| 50-day average | $201.51 | -13.4% |
| 200-day average | $152.18 | +14.7% |
Price Risk
Over 3 years, its largest fall from a peak was 87.9%.
| Measure | Value |
|---|---|
| 1-year beta | 1.67 |
| Largest fall, 1 year | -54.3% |
| Largest fall, 3 years | -87.9% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About NUTX
What is NUTX's 1-year price change?
Nutex Health's price rose 62.9% over the past 12 months. With dividends included, the 12-month total return was 62.9%.
What is NUTX's 5-year price change?
Nutex Health's month-end price fell 66.6% over the 5 years through Oct 2026, a compound annual decline of 19.7%. These figures leave out dividends.
What is NUTX's 52-week high and low?
Nutex Health's 52-week high is $226.16 and its 52-week low is $83.99. Its latest price of $174.51 on Nov 17, 2026 is 22.8% below the high.
What is NUTX's beta?
Nutex Health's 1-year beta against the S&P 500 is 1.67, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 54.3%.
Is the NUTX chart free?
Yes. Advanced Charting for NUTX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
NUTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors